Dr. Stratton on noteworthy aspect of trial of relugolix and enzalutamide in high-risk prostate cancer

In this video, Kelly L. Stratton, MD, FACS, discusses a noteworthy aspect of a phase 1B trial evaluating relugolix (Orgovyx) and enzalutamide (Xtandi) for high-risk prostate cancer. Stratton is an associate professor of urologic oncology at the University of Oklahoma, Oklahoma City.

Transcription:

What else would you like to add about this study?

I think that really the fact that this is completely an oral treatment, it makes it very easy for patients to manage and be involved with so they don't have to come and get shots. There are no infusions. Patients, I think, really benefit from that and are happy with that potential combination. And this study is supported by funding through the NCCN, and so that's a very important element for us. It's made it possible for us to open the study.

This transcription was edited for clarity.